Filing identity and reporting period
Important mismatch: The supplied filing is Aziyo Biologics, Inc.’s Form 10-K, not an Elutia Inc. filing. It reports the fiscal year ended December 31, 2020; standalone fourth-quarter results are not clearly provided in the supplied text. Aziyo is a commercial-stage regenerative medicine company selling products for cardiovascular and implantable-device procedures, orthopedic/spinal repair, soft-tissue reconstruction, and contract manufacturing.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Net sales | $42.7 million | $42.9 million |
| Gross profit / margin | $20.6 million / 48.2% | $19.8 million / 46.1% |
| Operating loss | $13.6 million | $8.4 million |
| Net loss | $21.8 million | $11.9 million |
| Cash used in operating activities | $13.6 million | $7.2 million |
- Core Products revenue grew 17.1% to $36.2 million; Non-Core Products revenue fell 46.0% to $6.5 million.
- Gross margin excluding intangible-asset amortization, a non-GAAP measure, was 56.1%, up from 54.0%.
- At December 31, 2020, cash and restricted cash totaled $39.5 million; working capital was supported by $59.7 million of current assets and $26.8 million of current liabilities. Inventory was $10.1 million.
- Debt included $19.7 million under the term loan, $6.5 million under the revolver, a $3.0 million PPP loan, and a $1.4 million supplier note. The revolver had $1.5 million of additional availability. Separately, the Ligand revenue-interest obligation had a reported carrying value of approximately $19.4 million.
- The October 2020 IPO generated approximately $43.0 million in net proceeds. Management expected IPO proceeds, cash, revolver availability, and expected sales to fund operations and capital needs through 2022, subject to assumptions that may prove incorrect.
Material changes and unusual items
- Total revenue declined 0.5% as Core Products growth was offset by lower contract-manufacturing sales. The company attributed the latter partly to a significant customer contract expiring in the first half of 2020.
- Operating expenses increased 21.2%, led by higher general and administrative costs and research and development spending. Management cited public-company costs, leadership additions, CanGaroo anti-infective development, and clinical activity.
- Other expense included a $2.3 million loss on early extinguishment of debt. A $3.5 million preferred-stock accretion was recorded in calculating loss attributable to common stockholders; it was not an operating expense.
- COVID-19-related postponements and cancellations of procedures hurt sales, particularly during the second quarter, and restricted sales-team access to healthcare settings.
Outlook, risks, and contingencies
- Management expected continued operating losses and expense growth as it expands sales, research, and clinical activities; the filing provides no specific revenue or earnings guidance.
- Key risks include ongoing losses and funding needs; dependence on commercial partners and a limited number of customers; reimbursement and pricing pressure; COVID-19 disruption; clinical and regulatory uncertainty; tissue-supply and manufacturing concentration; and competition. Medtronic represented 17% of 2020 sales and 34% of year-end receivables; Surgalign represented 10% of sales and 13% of receivables.
- Cook Biotech was the sole porcine-tissue supplier for CanGaroo and cardiovascular products. The company also depends on donated human tissue for other products.
- Debt agreements include a monthly minimum-revenue covenant, restrictive covenants, and liens on company assets. Aziyo reported compliance at year-end but disclosed past covenant breaches requiring waivers. Term-loan principal payments were scheduled to begin August 1, 2021, with maturity in July 2024.
- The $3.0 million PPP loan’s forgiveness was uncertain at filing; the company recorded it as a liability pending release from the obligation.
- Ligand receives 5% of sales of acquired CorMatrix products, subject to annual minimum payments of $2.75 million, with possible $5 million milestone payments at specified cumulative-sales thresholds. No material legal proceedings were reported.
- Management reported effective disclosure controls as of year-end. The filing did not include management’s internal-control assessment or an auditor attestation, citing the transition period for newly public companies.
Important facts for investors to verify
- Confirm the issuer: this document is Aziyo Biologics’ 2020 10-K, not Elutia Inc.’s filing.
- Review audited financial statements and debt notes for the complete debt, Ligand obligation, and covenant terms, including the timing of required payments.
- Assess whether Core Products growth can offset contract-manufacturing declines and COVID-related procedure disruption, and monitor customer concentration and receivable collections.
- Verify the status and amount of PPP loan forgiveness and the assumptions underlying management’s stated funding runway through 2022.
- Track regulatory and clinical progress, particularly CanGaroo with antibiotics and any SimpliDerm breast-reconstruction indication, which the filing said was not specifically FDA-cleared or approved.